Semaglutide Market Faces Slump with ₹100 Crore Excess Stock Overhang

The rapid ascent of the semaglutide weight-loss market has hit a significant roadblock as sluggish sales in May trigger an inventory crisis. Industry experts warn that a massive buildup of unsold stock is currently clogging the trade channel, threatening to dampen the momentum of this high-growth pharmaceutical segment.

The Inventory Crisis: A ₹100 Crore Glut

Following a massive surge in April, the semaglutide therapy market has encountered a sudden deceleration. According to industry sources and the All India Organisation of Chemists and Druggists (AIOCD), there is an estimated ₹100 crore worth of excess stock currently held by stockists and wholesalers.

This inventory overhang is particularly concerning because channel partners are now holding 50–60 days of stock, significantly higher than the industry standard of 30–45 days. As a result, wholesalers have hit a "pause" button on fresh procurement from pharmaceutical manufacturers, waiting for existing supplies to liquidate before placing new orders.

Analyzing the Growth Slowdown

The obesity therapy market, valued at approximately ₹2,000 crore, experienced a dramatic shift in momentum between April and May. In April, the market saw an explosive month-on-month (m-o-m) value growth of 50% and a volume surge of 88%. This was largely driven by the patent expiry of semaglutide on March 20, which allowed major players like Sun Pharma, Dr. Reddy’s, and Torrent to flood the market with cheaper generic versions.

However, the May data paints a different picture. According to Pharmarack, m-o-m value growth slowed to just 6%, while unit growth moderated to 12%. This cooling effect suggests that the initial rush of generic availability may have temporarily saturated the immediate demand.

Regulatory Hurdles and Market Competitors

Industry executives point toward regulatory shifts as a potential cause for the sales moderation. In April, new government guidelines stipulated that GLP-1 therapies must be prescribed only by qualified specialists. This restriction on prescribing patterns may have contributed to the sudden dip in consumer access and demand.

Despite the semaglutide slowdown, certain segments of the GLP-1 receptor agonist market remain resilient. Eli Lilly’s Mounjaro (tirzepatide) maintained its position as the largest selling therapy in the pharma market during May, with sales rising 12% to reach ₹136 crore. This indicates that while semaglutide faces an inventory hurdle, the broader demand for obesity and type 2 diabetes management remains a potent driver in India's ₹2.5 lakh crore organized pharma retail sector.

Key Takeaways

  • Inventory Overhang: Stockists are holding 50–60 days of semaglutide inventory, creating an estimated ₹100 crore excess stock in the trade channel.
  • Growth Deceleration: After an 88% volume surge in April, May saw value growth plummet to just 6% as manufacturers faced a pause in fresh orders.
  • Regulatory Impact: New government advisories requiring specialist-only prescriptions for GLP-1 therapies are suspected to be a key driver behind the sales moderation.